Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance.
Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance.
复制标题
在血液透析中的Covid-19患者中使用Remdesivir：安全性和耐受性的研究。
DOI：
10.1016/j.ekir.2020.12.003
复制
发表时间：
2021-03
影响因子：
6
通讯作者：
Sakthirajan R
中科院分区：
文献类型：
--
作者：
Aiswarya D;Arumugam V;Dineshkumar T;Gopalakrishnan N;Lamech TM;Nithya G;Sastry BVRH;Vathsalyan P;Dhanapriya J;Sakthirajan R
关于瑞姆得西韦用于严重急性呼吸窘迫综合征冠状病毒2型（SARS-CoV-2）和终末期肾病患者的数据很少，因为美国食品和药物管理局警告不要将其用于估计肾小球滤过率<30 ml/min/1.73m2的患者，除非潜在的益处超过潜在的风险。我们研究了remdesivir在终末期肾病和中度至重度SARS-CoV-2感染患者中的同情使用和安全性。我们对48例SARS-CoV-2感染的透析依赖患者进行了一项观察性前瞻性研究，这些患者接受了Remdesivir作为机构治疗方案的一部分。在治疗期间，在血液透析前4小时给予100 mg Remdesivir。比较雷米地韦治疗前后的肝功能检查、血清C反应蛋白、血清铁蛋白和乳酸脱氢酶等炎症标志物以及需氧量。给予2至6剂Remdesivir后，未发生显著的肝功能检查改变事件。血清C-反应蛋白水平显著下降（P <0.001）。超过三分之二（68.57%）的患者表现出氧需求的改善。在入院后48小时内早期给予Remdesivir可缩短平均5.5天的住院时间（P = 0.001）。Remdesivir耐受性良好，在我们的研究中发现安全。如果在住院后48小时内开始，它可以减少恢复时间。评估remdesivir在这些患者中的死亡率益处需要更大人群的随机对照试验。
There are scarce data regarding the use of remdesivir in patients with severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) and end-stage renal disease as US Food and Drug Administration cautions against its use in patients with an estimated glomerular filtration rate <30 ml/min/1.73m2 unless the potential benefits outweigh the potential risks. We studied the compassionate use and safety profile of remdesivir in patients with end-stage renal disease and moderate to severe SARS-CoV-2 infection. We conducted an observational prospective study in 48 dialysis-dependent patients with SARS-CoV-2 infection who received remdesivir as part of institutional treatment protocol. During the treatment period, 100 mg of remdesivir was given 4 hours before hemodialysis sessions. Liver function tests, inflammatory markers such as serum C-reactive protein, serum ferritin and lactate dehydrogenase levels, and oxygen requirement before and after remdesivir treatment were compared. There were no events of significant liver function test alterations with the administration of 2 to 6 doses of remdesivir. A significant decline in serum C-reactive protein level (P < 0.001) was noted. More than two thirds (68.57%) of patients showed an improvement in oxygen requirement. Early administration of remdesivir within 48 hours of hospital admission shortened the duration of hospitalization by a mean of 5.5 days (P = 0.001). Remdesivir was well tolerated and found safe in our study. If initiated within 48 hours of hospitalization, it reduces recovery time. Assessing the mortality benefits of remdesivir in these patients requires a randomized controlled trial with a larger population.
登录
查看更多内容
影响因子：
158.5
作者：
Grein, J.;Ohmagari, N.;Flanigan, T.
通讯作者：
Flanigan, T.
DOI：
10.2215/cjn.01390406
发表时间：
2006-09-01
影响因子：
9.8
作者：
Kalantar-Zadeh, Kamyar;Kalantar-Zadeh, Kourosh;Lee, Grace H.
通讯作者：
Lee, Grace H.
影响因子：
6
作者：
Thakare S;Gandhi C;Modi T;Bose S;Deb S;Saxena N;Katyal A;Patil A;Patil S;Pajai A;Bajpai D;Jamale T
通讯作者：
Jamale T
影响因子：
11.8
作者：
Luo, Xiaomin;Zhou, Wei;Yang, Weize
通讯作者：
Yang, Weize
影响因子：
158.5
作者：
Beigel, John H.;Tomashek, Kay M.;Lane, H. Clifford
通讯作者：
Lane, H. Clifford